Articles

20 stocks that bucked the stock market’s decline in March with double-digit gains

Energy stocks have fared well as crude-oil prices have shot up, but one other industry group has also done well since the U.S. and Israel attacked Iran on Feb. 28.

Consumer confidence improves in March as brighter job-market view outweighs surging costs amid Iran war

Consumers expect higher inflation and interest rates in coming months.

CoreWeave’s stock rises as investors cheer unique financing deal

This is the first time that a loan backed by compute hardware has achieved investment-grade status.

Pension funds could ride to the stock market’s rescue as retail investors step back

Tuesday marks the final day of what has been a tumultuous quarter for global financial markets.

Snowflake’s stock falls as investors weigh a surprise leadership shift

Mike Gannon, the software company’s chief revenue officer, is departing for personal reasons after a year in the role.

These 20 stocks in the S&P 500 fell hardest during March

These stocks saw significant declines in the month.

Apple turns 50. Here’s how it can shake its midlife crisis.

After successfully conquering the smartphone and PC market, Apple must now prove that it can innovate for the AI era.

Marvell’s stock soars. What’s behind the new Nvidia investment and partnership.

Nvidia is pouring $2 billion into Marvell, marking its latest investment within the AI ecosystem.

Lilly to pay up to $7.8 billion to buy a company developing a narcolepsy drug

The company, which is flush with cash from sales of its market-leading GLP-1 franchise, has been an active dealmaker.

It’s time to get defensive, say Morgan Stanley strategists. Hold more cash and make these moves.

Strategists lowered their rating on global stocks while saying investors should hold onto more cash and U.S. Treasury securities.

Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases

Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis Pharmaceuticals

McCormick looks to merge with Unilever’s food business, but there’s no mention in earnings report

McCormick’s stock surges amid talks to combine with Unilever’s foods business, but there’s no mention of the deal in the earnings report.
1 149 150 151 152 153 2,639